Results 61 to 70 of about 1,045,119 (218)
Drug–Drug Interactions in Patients with Brucellosis: A Retrospective Analysis
Mediterranean Journal of Infection, Microbes and AntimicrobialsIntroduction: The prolonged duration of drug treatment and the need for combination therapy in brucellosis increase the risk of drug-related problems. One of the most significant drug-related problems is drug–drug interactions.
Bahar Çelebi +3 more
doaj +1 more source
Transporter-Mediated Drug–Drug Interactions with Oral Antidiabetic Drugs
Pharmaceutics, 2011 Uptake transporters (e.g., members of the SLC superfamily of solute carriers) and export proteins (e.g., members of the ABC transporter superfamily) are important determinants for the pharmacokinetics of drugs.
Jörg König +2 more
doaj +1 more source
Structure‐forward targeting of claudins with synthetic binders
FEBS Letters, EarlyView.Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley +1 more source
Discerning protein pools by selective staining with self‐labeling tags
FEBS Letters, EarlyView.Cell surface proteins have an intra‐ and extracellular pool. Combining genetic fusion to self‐labeling tags that can be addressed with small molecule fluorophores allows separating these pools. We highlight recent developments and techniques for state‐of‐the‐art interrogation of cell surface proteins in the complex tissue setting.
Kati Fischermanns, Johannes Broichhagen
wiley +1 more source
Journal of CheminformaticsIn drug development, managing interactions such as drug–drug, drug–disease, and drug–nutrient is critical for ensuring the safety and efficacy of pharmacological treatments.
Nour H. Marzouk +4 more
doaj +1 more source
Drugs and Drug CandidatesBackground: Bacterial resistance to antimicrobial drugs is a critical phenomenon that is hampering clinical treatments, raising the need for promising compounds that can be explored as pharmaceutical products.
Washington de Souza Leal +5 more
doaj +1 more source
Metabolism, Transport and Drug–Drug Interactions of Silymarin
Molecules, 2019 Silymarin, the extract of milk thistle, and its major active flavonolignan silybin, are common products widely used in the phytotherapy of liver diseases.
Ying Xie +3 more
doaj +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Liver organoids: modelling complexity in homeostasis and disease
FEBS Letters, EarlyView.Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley +1 more source
Epigenetic reprogramming of lineage switching in cancer
FEBS Letters, EarlyView.Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı +4 more
wiley +1 more source